Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507

Tel :+91 40 4900 2900
Fax :+91 40 4900 2999
Email :mail@drreddys.com
www.drreddys.com

November 18, 2019

Surveillance Department
BSE Limited
Dalal Street, Fort
Mumbai – 400 001
Fax Nos.: 022-22723121 / 22723719

Scrip Code: 500124

National Stock Exchange of India Ltd.
"Exchange Plaza"
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237

Scrip Code: DRREDDY-EQ

Dear Sirs,

Ref.: Your email dated November 18, 2019

Sub: Clarification/Confirmation on news item appearing in "www.moneycontrol.com"

This is with reference to your email dated November 18, 2019, seeking clarification/Confirmation on news item appearing in www.moneycontrol.com, dated November 18, 2019 captioned *"Wockhardt: Cipla, Dr. Reddy's Labs, Carlyle & Asian Investment Fund PAG are in the fray to acquire select business segments of the company, said sources"* and also regarding the Company's share price movement

In this regard, we would like to state that the reports appearing in certain sections of the media relating to M&A activities of Dr. Reddy's are purely speculative. We keep on exploring various opportunities for acquisition and in-licensing/out-licensing activities as part of our normal business practices.

The Company would further like to clarify that its policy is not to comment on rumors or speculations and it has always complied with its reporting obligations under SEBI (LODR) Regulations, 2015, in a timely manner, and will continue to do so.

Further, the movement in price of the Company's scrip is completely market driven and hence the Company has no comments to offer on share price movement.

This is for your information.

With regards,

Sandeep Poddar
Company Secretary